

TEG PlateletMapping assay results may be misleading in the presence of cold stored platelets

Thomas G. Scorer^{1,2,3}, Lucy FitzGibbon,² Riyaad Aungraheeta,² Umang Sharma,³ Grantham C. Peltier,³ Colby S. McIntosh,³ Kristin M. Reddoch-Cardenas^{1,3}, Andrew Meyer,^{3,4} Andrew P. Cap,³ and Andrew D. Mumford²

BACKGROUND: Viscoelastic tests (VETs) are used widely to monitor hemostasis in settings such as cardiac surgery. There has also been renewed interest in cold stored platelets (CSPs) to manage bleeding in this setting. CSPs are reported to have altered hemostatic properties compared to room temperature platelets (RTPs), including activation of GPIIb/IIIa. We investigated whether the functional differences between CSP and RTP affected the performance of the PlateletMapping VET on the TEG 5000 and 6s analyzer.

METHOD: Platelet concentrates were divided equally into CSP (stored at 4°C ± 2°C) and RTP (stored at 22°C ± 2°C) fractions. Whole blood was treated to induce platelet dysfunction (WBIPD) by incubating with anti-platelet drugs (1.0 μM ticagrelor and 10 μM aspirin) or by simulating cardiopulmonary bypass. WBIPD samples were then mixed with 20% by volume of CSPs or RTPs to model platelet transfusion before analysis using the PlateletMapping VET.

RESULTS: Addition of CSPs to WBIPD increased the PlateletMapping MA_{FIBRIN} and MA_{ADP} parameters with the TEG 5000 analyzer (both p < 0.0001 compared to addition of buffer alone). This effect was not observed with RTPs. The differential effect of CSPs on the MA_{FIBRIN} corrected after pre-incubation with the GPIIb/IIIa antagonist tirofiban and was quantitatively less with the PlateletMapping test for the TEG 6s analyzer which contains the GPIIb/IIIa antagonist abciximab.

DISCUSSION: The PlateletMapping MA_{FIBRIN} and MA_{ADP} test results may be misleadingly high with CSPs, particularly with the TEG 5000 analyzer, most likely due to constitutive activation of GPIIb/IIIa on CSPs during storage. TEG PlateletMapping results should be interpreted with caution following CSP transfusion.

The use of viscoelastic hemostatic tests (VETs) to guide resuscitation during major hemorrhage has increased significantly in recent years and is now recommended by the National Institute for Health and Care Excellence (NICE) for cardiac surgery.¹ VETs are also used commonly in other clinical settings such as traumatic or obstetric hemorrhage, but are not formally recommended in practice guidelines because evidence supporting clinical benefit remains incomplete.²⁻⁵

In both of the two most widely adopted VET technologies thromboelastography (TEG; Haemonetics) and rotational thromboelastometry (ROTEM; TEM International), clot formation is initiated using specific activators in whole blood

From the ¹Centre of Defence Pathology, Royal Centre of Defence Medicine, Birmingham; ²School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK; the ³Coagulation and Blood Research, U.S. Army Institute of Surgical Research, Fort Sam Houston, and the ⁴Division of Pediatric Critical Care, Department of Pediatrics, University of Texas Health Science Center, San Antonio, Texas.

Address reprint requests to: Tom G. Scorer, Research Floor Level 7, University of Bristol, Bristol Royal Infirmary, Bristol, BS2 8HW, UK; e-mail: tom.scorer@bristol.ac.uk.

Disclaimer: TS was funded by Ministry of Defence. The study was supported by the U.S. Army Medical Research and Materiel Command, NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Department of the Army, the U.S. Department of Defense, the Ministry of Defence, the National Institute for Health Research, or the Department of Health.

This article is published with the permission of the Controller of HMSO and the Queen's Printer for Scotland.

Received for publication November 5, 2019; revision received January 28, 2020, and accepted February 24, 2020.

doi:10.1111/trf.15753


© 2020 Crown copyright. Transfusion © 2020 AABB

TRANSFUSION 2020;60;S119-S123

samples housed in analysis cups with a suspended pin. Clot viscoelastic strength is then monitored continuously by detecting the mechanical resistance to oscillations applied to either cup (TEG) or pin (ROTEM).

Early versions of these VETs using contact (TEG-Kaolin test) or extrinsic pathway (ROTEM-EXTEM test) activators did not distinguish the specific contributions of either fibrin or platelets to clot strength. However, subsequent refinements of VETs utilize selective coagulation activators and platelet inhibitors to more precisely phenotype clot formation.^{6,7} One example is the TEG PlateletMapping system which enables the platelet contribution to clot strength to be inferred from three different measurements of the maximum amplitude (MA) of the test traces⁸⁻¹⁰: 1) MA_{THROMBIN} obtained using the standard TEG Kaolin activator, which stimulates thrombin generation in the blood sample. This parameter reflects the thrombin-dependent contributions of fibrin plus platelets to clot strength. 2) MA_{FIBRIN} obtained using ActivatorF, containing reptilase and FXIII to generate and stabilize fibrin clot independently of thrombin. This reflects the fibrin component. 3) $MA_{\text{ADP/AA}}$ in which ActivatorF is combined with the direct platelet activators adenosine di-phosphate (ADP) or arachidonic acid (AA). This reflects the contribution of platelet ADP or AA pathways to clot strength. The main “% inhibition/aggregation” parameter from TEG PlateletMapping system is derived from the three MA measurements (Fig. 1) and represents the contribution of either ADP-mediated or AA-mediated platelet activation to clot strength. This enables detection of the antiplatelet drugs aspirin (inhibits AA-mediated platelet function) and P2Y₁₂-blockers (inhibit ADP-mediated platelet function), which is critical in settings such as cardiac surgery to quantify the impact of anti-platelet drugs on clot strength and to guide platelet transfusion. Although initially developed for the TEG 5000 analyzer, the TEG PlateletMapping system has now been refined for the cartridge-based TEG 6s analyzer. For this analyzer, the ActivatorF reagent used to measure the MA_{FIBRIN} also includes the potent GPIIb/IIIa receptor antagonist abciximab.¹⁰ This prevents platelet-fibrin interactions ensuring that the MA_{FIBRIN} only reflects the fibrin component of clot strength, thereby enabling a more reliable calculation of platelet “percentage inhibition/aggregation.”

One important trend in transfusion practice is the emergence of evidence that cold stored platelets (CSPs) may be a useful alternative to conventional room temperature platelets (RTPs) in settings such as trauma or cardiac surgery.¹¹⁻¹⁵ It is established that CSPs have altered expression of several surface adhesive receptors including GPIIb/IIIa, and also increased basal platelet activation compared to RTP.¹⁶⁻¹⁹ Since these characteristics are critical for the endpoints of the TEG PlateletMapping test, we investigated whether CSPs had a different effect on test results compared to RTPs when platelets were mixed with coagulopathic blood samples to simulate platelet transfusion.



$$\% \text{ aggregation} = \frac{MA_{\text{ADP/AA}} - MA_{\text{FIBRIN}}}{MA_{\text{THROMBIN}} - MA_{\text{FIBRIN}}} \times 100$$

$$\% \text{ inhibition} = 100 - \% \text{ aggregation}$$

Fig. 1. TEG PlateletMapping assay percentage (%) inhibition/aggregation is calculated from the maximal amplitude (MA) of three TEG assays; MA_{THROMBIN} obtained using the standard TEG Kaolin activator, which stimulates thrombin generation in the blood sample. This parameter reflects the thrombin-dependent contributions of fibrin plus platelets to clot strength. MA_{FIBRIN} obtained using ActivatorF, containing reptilase and FXIII to generate and stabilize fibrin clot independently of thrombin. This reflects the fibrin component. $MA_{\text{ADP/AA}}$ in which ActivatorF is combined with the direct platelet activators adenosine di-phosphate (ADP) or arachidonic acid (AA). This reflects the contribution of platelet ADP or AA pathways to clot strength. The equation shown is used to calculate the “% aggregation” parameter from the three MA measurements and represents the contribution of either ADP-mediated or AA-mediated platelet activation to clot strength. Percentage (%) inhibition = 100 – % aggregation.

MATERIALS AND METHODS

Preparation of platelet concentrates

Apheresis platelets were collected from healthy volunteers using the Trima Accel system (TerumoBCT) as previously described.^{17,20-22} Platelets were collected as hyper-concentrated double collections, before being split equally into two platelet storage bags (Polyolefin PL-2410, Fenwal) within 2 hours. Pooled buffy coat platelets were manufactured by NHS Blood and Transplant (NHSBT) as previously described²³ in compliance with Blood Safety and Quality Regulations, Statutory Instrument 2005 No.50.²⁴ Both preparations were suspended in 35% plasma and 65% platelet additive solution (T-PAS, TerumoBCT for apheresis and SSP+; MacoPharma for buffy-coat platelets). Buffy-coat platelet concentrates were separated

aseptically 24-36 hours after donation into two equal volumes into two TOTM bags (MacoPharma). The paired platelet concentrates were then stored at $22^{\circ}\text{C} \pm 2^{\circ}\text{C}$ with continuous agitation (RTPs) or at $4^{\circ}\text{C} \pm 2^{\circ}\text{C}$ without agitation (CSPs).

Preparation of whole blood with induced platelet dysfunction (WBIPD) samples

Whole blood (WB) was collected from healthy volunteers by peripheral venipuncture into 3.2% trisodium citrate tubes (BD Biosciences) in compliance with the Declaration of Helsinki. Two platelet dysfunction models were simulated and in this analysis are considered together ($n = 14$): 1) *dual anti-platelet therapy*, incubation with $1.0 \mu\text{M}$ ticagrelor and $10 \mu\text{M}$ acetylsalicylic acid (ASA) for a minimum of 15 minutes ($n = 8$ samples); and 2) *extracorporeal bypass*, WB collected into a 500 mL Capiox reservoir (TerumoBCT) containing 1 IU/mL heparin sulfate then circulated through an extracorporeal bypass circuit containing a roller pump (Cobe CV Model 43600, Sorin Biomedica), blood oxygenator (KIDS D100 Oxygenator, Sorin Biomedica), and pressure monitoring catheters (DLP catheters, 8 Fr, 12 Fr, Medtronic). Blood was circulated at a flow rate of 0.5 L/min with samples taken for analysis after 6 hours ($n = 6$ samples).

Mixing experiments and PlateletMapping analysis

Apheresis CSPs or RTPs stored between 3 and 7 days were mixed with WBIPD samples at a dose of 20% by volume. In

control experiments, the same volume of PlasmaLyte A pH 7.4 (Baxter) was mixed with the WBIPD samples. The sample mixtures were analyzed using the TEG 5000 analyzer according to manufacturer's guidelines.¹⁰ In additional experiments to study the effect of additional GPIIb/IIIa inhibition, buffy coat CSPs were incubated with tirofiban (Correio Pharma Corp.) for at least 15 minutes and analyzed on both TEG 5000 and 6s platforms. Data were compared by analysis of variance (ANOVA) performed using GraphPad Prism version 8.2.1 (GraphPad Software).

RESULTS

Addition of both CSPs and RTPs increased the TEG 5000 $\text{MA}_{\text{THROMBIN}}$ in the WBIPD samples (both $p < 0.001$ compared to addition of buffer alone, $n = 14$, Fig. 2A), consistent with reversal of thrombocytopeny. As expected, the TEG 5000 $\text{MA}_{\text{FIBRIN}}$ was not altered by the addition of RTPs to WBIPD. However, CSPs substantially increased the $\text{MA}_{\text{FIBRIN}}$ ($p < 0.0001$ compared to addition of buffer alone, $n = 14$, Fig. 2B). There was a small, but non-significant increase in TEG 5000 MA_{ADP} with RTPs, but a significant increase with CSPs ($p < 0.0001$ compared to addition of buffer alone, $n = 14$, Fig. 2C). The net effect of the differences in $\text{MA}_{\text{FIBRIN}}$ and MA_{ADP} between RTPs and CSPs was an apparent reduction in the derived percentage aggregation parameter with




Fig. 2. TEG 5000 PlateletMapping assay maximal amplitude (MA) and calculated percentage (%) aggregation of: whole blood with induced thrombocytopeny (WBIPD) and addition of 20% v/v buffer alone, WBIPD with a simulated transfusion of 20% v/v, cold stored platelets (WBIPD + CSPs), and WBIPD with a simulated transfusion of 20% v/v, room temperature stored platelets (WBIPD + RTPs) ($n = 14$).

A - $\text{MA}_{\text{THROMBIN}}$, B - $\text{MA}_{\text{FIBRIN}}$, C - MA_{ADP} and D - Calculated Percentage (%) aggregation. Statistical significance relative to WBIPD

* = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$, ns = non-significance.




Fig. 3. TEG MA_{FIBRIN} dose response curve illustrating tirofiban treatment of pooled buffy coat CSPs (n = 3) with the TEG 5000 analyzer, R² = 0.93, 95% confidence intervals, standard error of the mean (SEM).

CSPs. However, because of the broad variation in results, this did not reach statistical significance (Fig. 2D).

One explanation for the increased MA_{FIBRIN} with CSPs was that increased constitutive activation of GPIIb/IIIa could potentially cause the CSP to contribute to clot strength even though platelets are not directly activated with the ActivatorF reagent that is used to measure the MA_{FIBRIN}. In order to test this, the CSPs were incubated with the GPIIb/IIIa antagonist tirofiban before mixing with WBIPD and testing using the TEG 5000 platform. The addition of tirofiban resulted in a dose-dependent decrease in MA_{FIBRIN} with CSPs, resulting in values similar to those with RTPs at tirofiban concentrations above 1 mM (Fig. 3). In order to assess whether the inclusion of abciximab in the MA_{FIBRIN} channel of the TEG 6s PlateletMapping cartridge reduces the CSP MA_{FIBRIN} in the same way as tirofiban, three samples of CSP products were analyzed on both TEG 5000 and 6s analyzers simultaneously. The MA_{FIBRIN} was 56.2 ± 3.28 mm (mean ± SEM) and 45.2 ± 3.0 mm for TEG 5000 and TEG 6s, respectively, a reduction of 11 mm (19.6%) with TEG 6s.

Together, these observations support that the increased MA_{FIBRIN} with CSPs compared to RTPs was mostly mediated by activated GPIIb/IIIa on CSPs and that this particularly impacts on the unmodified TEG 5000 PlateletMapping test because a GPIIb/IIIa antagonist is absent.

DISCUSSION

The TEG PlateletMapping assay has proved valuable in the management of patients, especially cardiac surgery patients in which there is frequently a complex thrombocytopeny that includes the effects of anti-platelet and the mechanical effect of cardiopulmonary bypass.^{2,3,5} The calculation of percentage inhibition/aggregation with ADP or AA is essential to resolve the degree of platelet dysfunction. However, this derived parameter relies on the MA_{FIBRIN} being an accurate representation of the

contribution of fibrin to clot strength which can then be subtracted from the MA_{THROMBIN} and MA_{ADP/AA} to yield the respective platelet contributions. Our results demonstrate that particularly with the TEG 5000 PlateletMapping test, this assumption may not be valid in the presence of CSPs with which there is a dramatic increase in MA_{FIBRIN} compared with equivalent quantities of RTPs. This differential effect was also observed with the MA_{ADP} result, which together resulted in a trend toward apparent underestimation of the percentage aggregation parameter in the presence of CSPs.

We show further that the differential effect of CSPs on the TEG 5000 PlateletMapping MA_{FIBRIN} can be ameliorated by the addition of the GPIIb/IIIa antagonist tirofiban. This observation is consistent with previous observations that cold storage of platelets results in constitutive activation of GPIIb/IIIa enabling binding of free fibrinogen in plasma, a process responsible for the formation of platelet clumps during cold storage in fibrinogen-rich medium.¹⁹ The bound fibrinogen may also complex for FXIII, providing a nucleation site for fibrin polymerization.¹⁷ We propose that addition of ActivatorF containing activated FXIII and reptilase for measurement of the PlateletMapping MA_{FIBRIN} and MA_{ADP}, results in crosslinked fibrin formation, but also recruitment of CSPs to contribute to clot strength, even though they are not directly activated by the test reagents. This effect is not observed with RTPs because GPIIb/IIIa activation is minimal at room temperature storage. Consistent with this, the impact of CSPs on MA_{FIBRIN} is less in the PlateletMapping test developed for the TEG 6s analyzer, because of the inclusion of the GPIIb/IIIa antagonist abciximab, although still present. The partial reduction in MA_{FIBRIN} in the TEG 6s with CSPs may indicate that the dose of abciximab in the cartridge is insufficient. These findings indicate that the TEG 6s assay has the potential to be optimized further to mitigate against misleading results. In the meantime, our data suggest that caution should be exercised in interpreting TEG PlateletMapping results in the presence of CSPs. Further validation, ideally in the *in vivo* setting is required to ensure patients are not put at risk.

ACKNOWLEDGMENTS

Thank you to Mr Chris Taswell (Bristol Royal Infirmary, cardiac theaters) for facilitating the use of TEG 5000 and 6s analyzers and to Haemonetics for kindly supplying TEG PlateletMapping reagents for part of this study.

CONFLICT OF INTEREST

The authors have disclosed no conflicts of interest.

REFERENCES

1. National Institute for Health and Care Excellence (NICE). Diagnostics guidance 13: detecting, managing and monitoring haemostasis: viscoelastometric point-of-care testing (ROTEM,

- TEG and Sonoclot systems). 2014 [cited 2019 Sept 21]. Available from: <https://www.nice.org.uk/guidance/dg13>.
2. Whiting P, Al M, Westwood M, et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. *Health Technol Assess* 2015;19:1-228, v-vi.
 3. Serraino GF, Murphy GJ. Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: updated systematic review and meta-analysis. *Br J Anaesth* 2017;118:823-33.
 4. Hunt BJ, Allard S, Keeling D, et al. A practical guideline for the haematological management of major haemorrhage. *Br J Haematol* 2015;170:788-803.
 5. Curry NS, Davenport R, Pavord S, et al. The use of viscoelastic haemostatic assays in the management of major bleeding: a British Society for Haematology Guideline. *Br J Haematol* 2018;182:789-806.
 6. Peng HT, Nascimento B, Beckett A. Thromboelastography and thromboelastometry in assessment of fibrinogen deficiency and prediction for transfusion requirement: a descriptive review. *Biomed Res Int* 2018;2018:7020539.
 7. Stettler GR, Sumislawski JJ, Moore EE, et al. Citrated kaolin thrombelastography (TEG) thresholds for goal-directed therapy in injured patients receiving massive transfusion. *J Trauma Acute Care Surg* 2018;85:734-40.
 8. Sivapalan P, Back AC, Ostrowski SR, et al. Transfusion requirements in elective cardiopulmonary bypass surgery patients: predictive value of Multiplate and Thromboelastography (TEG) Platelet Mapping Assay. *Scand J Clin Lab Invest* 2017;77:345-51.
 9. Bochsén L, Wiinberg B, Kjølgaard-Hansen M, et al. Evaluation of the TEG platelet mapping assay in blood donors. *Thromb J* 2007;5:3.
 10. TEG system. Haemonetics. [cited 2019 Sept 21]. Available from: <https://teg.haemonetics.com/en>.
 11. Reddoch-Cardenas KM, Bynum JA, Meledeo MA, et al. Cold-stored platelets: a product with function optimized for hemorrhage control. *Transfus Apher Sci* 2019;58:16-22.
 12. Berzuini A, Spreafico M, Prati D. One size doesn't fit all: should we reconsider the introduction of cold-stored platelets in blood bank inventories? *F1000Res* 2017;6:95.
 13. Apelseh TO, Cap AP, Spinella PC, et al. Cold stored platelets in treatment of bleeding. *ISBT Sci Ser* 2017;12:488-95.
 14. Cap AP. Targeting hemorrhage: alternative storage of platelets for hemostatic transfusion. *Blood* 2017;130:SCI-32.
 15. Milford CEM, Reade CMC. Comprehensive review of platelet storage methods for use in the treatment of active hemorrhage. *Transfusion* 2016;56:S140-S8.
 16. Reddoch KM, Pidcock HF, Montgomery RK, et al. Hemostatic function of apheresis platelets stored at 4°C and 22°C. *Shock* 2014;41:54-61.
 17. Nair PM, Pandya SG, Dallo SF, et al. Platelets stored at 4°C contribute to superior clot properties compared to current standard-of-care through fibrin-crosslinking. *Br J Haematol* 2017;178:119-29.
 18. Wood B, Padula MP, Marks DC, et al. Refrigerated storage of platelets initiates changes in platelet surface marker expression and localization of intracellular proteins. *Transfusion* 2016;56:2548-59.
 19. Getz TM, Montgomery RK, Bynum JA, et al. Storage of platelets at 4°C in platelet additive solutions prevents aggregate formation and preserves platelet functional responses. *Transfusion* 2016;56:1320-8.
 20. Montgomery RK, Reddoch KM, Evani SJ, et al. Enhanced shear-induced platelet aggregation due to low-temperature storage. *Transfusion* 2013;53:1520-30.
 21. Reddoch KM, Montgomery RK, Rodriguez AC, et al. Endothelium-derived inhibitors efficiently attenuate the aggregation and adhesion responses of refrigerated platelets. *Shock* 2016;45:220-7.
 22. Scorer T, Sharma U, Peltier G, et al. Ticagrelor induced platelet dysfunction can be assessed under shear conditions and correction by platelets is influenced by storage temperature. *Blood* 2018;132:526.
 23. JPAC. Guidelines for the blood transfusion services in the UK: 8th edition red book. 2013 [cited 2019 Sept 21]. Available from: <https://www.transfusionguidelines.org/red-book>.
 24. Blood safety and quality regulations 2005 UK Statutory Instrument No.50 2005 [cited 2019 Sept 21]. Available from: <http://www.legislation.gov.uk/uksi/2005/50/contents/made>. 